1. Peiwen Fei University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, USA.
2. Jennifer Grandis Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, USA.
3. Bogdan Grechko Plastic and Reconstructive Oncological Urology, National cancer Institute, Ukraine.
4. James A Solomon University of Central Florida College of Medicine, Orlando, Florida, USA.
5. Consolato Sergi Stollery Children's Hospital, University of Alberta, Edmonton, Canada.
6. S Balakrishna Pai Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory School of Medicine, Atlanta, USA.
7. Xiuwei Yang Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, University of Kentucky Lexingto, Lexington, USA.
8. George P. Studzinski Department of Pathology, Immunology and Laboratory Medicine, Rutgers New Jersey Medical School, Newark, USA.
9. Jennifer R Grandis Department of Otolaryngology, University of California, San Francisco, USA.
10. Jennifer H Gunter School of Biomedical Science, Institute of Health & Biomedical Innovation, Queensland University of Technology located within the Translational Research Institute, Brisbane, Australia.
11. Mohamed Hassan Department of Surgery, Tulane University School of Medicine, New Orleans, USA.
12. Luis Vitetta The University of Sydney, Faculty of Medicine and Health, Sydney, Australia.
13. Antonella Papa Cancer Research Institute, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
14. Audrey Minden Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, USA.
15. Anait S Levenson Department of Biomedical Sciences, School of Veterinary Medicine, Long Island University, Brookville, USA.
16. Dhimant Desai Penn State Cancer Institute, Pennsylvania State University College of Medicine, Hershey, United States.
17. Edna Teruko Kimura Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
18. Karen C Crasta Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
19. Yihua Wang Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK.
20. Ravi P Sahu Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, Dayton, USA.
21. Sajeel Chowdhary Neuro-Oncology Program, Lynn Cancer Institute, Boca Raton, USA.
22. Kelly Grace Magalhaes Laboratory of Immunology and Inflammation, Department of Cell Biology, University of Brasilia, Distrito Federal, Brazil.
23. Shanta M Messerli Department of Biomedical Engineering, University of South Dakota, Sioux Falls, USA.
The list is arranged in no particular order and being updated.
Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jcmtjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/JCMT/?IssueId=366
Submission Deadline: 30 Jun 2020
Contacts: Monica Gao, assistant editor, firstname.lastname@example.org
Type: Original Article
Title: Cellular signaling pathways activated by α-Mangostin during induction of cell death in human esophageal adenocarcinoma
Authors: S. Balakrishna Pai
Affiliations: Director of Instructional Laboratories，Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University.
Abstract: Aim: Alpha mangostin, a xanthone from mangosteen fruit, has been reported to have beneficial effects against various cancers. However, the potential of this molecule against esophageal adenocarcinoma has not been investigated in detail. The current study sought to investigate the cytotoxic effect of α-mangostin on the esophageal carcinoma cell line OE33 as well as elucidate the mechanism of action.
Methods: A Cell Counting Kit-8 assay was used to assess the cell viability after treatment with α-mangostin. Additionally, multicaspase, cell cycle, and mitopotential flow cytometric assays were also performed to further assess the contribution of various signaling pathways on α-mangostin-induced cell death of OE33 cells.
Results: Cell Counting Kit-8 assay indicated that cell viability was significantly reduced in a dose-dependent manner after 72 hours of α-mangostin treatment. After assessing the cells via an Annexin V & Dead Cell Kit at 24, 48, and 72 hours, it was determined that OE33 cells underwent early apoptosis after only 24 hours of treatment at a concentration of 15 µM. α-mangostin treatment did not significantly change the mitochondrial potential nor did it impact the cell cycle progression. Further, detailed analysis of apoptosis signaling pathway indicated that caspase cascade could be responsible for reduction in cell viability of treated cells. α-mangostin induces apoptosis at an early timepoint in OE33 cells and does so at a relatively low concentration.
Conclusion: Taken together, data from the current study, in addition to deciphering the signaling pathways, highlight the potential therapeutic potential of α-mangostin against esophageal adenocarcinoma.